GentiBio and BMS partner to develop inflammatory bowel disease therapies
BMS will make development and commercial milestone payments of up to $1.9bn to GentiBio.

BMS will make development and commercial milestone payments of up to $1.9bn to GentiBio.
The latest approval is based on findings from three randomised, multicentre, Phase III trials of Rinvoq.
For the fiscal year, the operating cash flow witnessed a 11.1% rise to $8.63bn (JPY1,123.1bn).
Key opinion leaders expect Dupixent to target patients who do not respond to current oeosinophilic oesophagitis (EoE) therapies.
ByThe proceeds will be used to advance the development of its compounds currently in clinical trials.
Arena’s portfolio includes several candidates in gastroenterology, dermatology and cardiology.
We've analysed 10 years' worth of clinical trials data from GlobalData to pick out key geographic trends.
ByGlobalData anticipates a dynamic eosinophilic esophagitis market with a range of treatment options in the coming years.
ByThank you for subscribing to Pharmaceutical Technology